Anita Mamtani, MD, on When Can Axillary Dissection Be Avoided in Patients With Breast Cancer?

Posted: Friday, May 12, 2023

Anita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses the clinical implications of study findings on whether axillary lymph node dissection is required for patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. Neoadjuvant chemotherapy did not appear to reduce the risk of lymph node dissection in this cohort, although upfront surgery allowed for de-escalated chemotherapy regimens.

---